Rome IV Diagnostic Criteria for Reflux Hypersensitivity

Apply the Rome IV diagnostic criteria for Reflux Hypersensitivity (A3). Evaluate retrosternal symptoms, endoscopy findings, motor disorder exclusion, reflux-symptom association with normal acid exposure, and temporal requirements. Free online clinical calculator for educational use.

Rome IV Reflux Hypersensitivity Criteria

Check the criteria that apply to the patient. The Rome IV criteria for Reflux Hypersensitivity (A3) require all four diagnostic criteria plus the temporal criteria to be satisfied. Response to antisecretory therapy does not exclude the diagnosis.

Diagnostic criteria (all required)

Must include all of the following.

Temporal criteria (all required)

Symptoms must meet the following time and frequency thresholds.

Disclaimer: The Rome IV diagnostic criteria for Reflux Hypersensitivity are an educational clinical decision-support tool. They do not replace comprehensive clinical evaluation, appropriate diagnostic workup (endoscopy with biopsies, ambulatory reflux monitoring, high-resolution manometry), or clinical judgment. Always ensure structural, reflux-mediated, and eosinophilic causes have been appropriately evaluated before applying these criteria.

Rome IV Reflux Hypersensitivity: criteria, workup, and clinical context

Overview

Reflux Hypersensitivity (Rome IV category A3) is a functional esophageal disorder introduced in 2016 as part of the Rome IV classification. Previously termed the "hypersensitive esophagus," it is characterized by retrosternal symptoms (heartburn and/or chest pain) triggered by reflux events despite normal esophageal acid exposure. The positive symptom-reflux association on ambulatory monitoring is the hallmark feature that distinguishes reflux hypersensitivity from functional heartburn (A2). Response to antisecretory therapy does not exclude the diagnosis.

Diagnostic criteria

Must include all of the following:

#	Criterion	Clinical interpretation
1	Retrosternal symptoms including heartburn and chest pain	Typical reflux-type symptoms localized behind the sternum. Both heartburn and chest pain are included in the Rome IV definition.
2	Normal endoscopy and absence of evidence that EoE is the cause	Upper endoscopy shows no erosive esophagitis or Barrett esophagus. Esophageal biopsies must exclude eosinophilic esophagitis (<15 eosinophils per high-power field).
3	Absence of major esophageal motor disorders	High-resolution manometry must exclude achalasia/EGJ outflow obstruction, diffuse esophageal spasm (DES), jackhammer esophagus, and absent peristalsis per the Chicago Classification v4.0.
4	Evidence of triggering of symptoms by reflux events despite normal acid exposure	Ambulatory pH or pH-impedance monitoring shows normal acid exposure time (AET <4%) but a positive symptom-reflux association (symptom index ≥50% or symptom association probability ≥95%). This positive association is the key distinguishing feature from functional heartburn.

Temporal criteria

Requirement	Detail
Duration	Criteria fulfilled for the last 3 months
Onset	Symptom onset at least 6 months before diagnosis
Frequency	At least twice per week

These temporal requirements are standard across most Rome IV functional esophageal disorder categories (A1 through A5).

Distinguishing reflux hypersensitivity from related conditions

Condition	Acid exposure	Symptom-reflux correlation	PPI response
Erosive GERD	Abnormal	Usually positive	Good
NERD	Abnormal	Positive	Moderate
Reflux hypersensitivity (A3)	Normal	Positive	Variable
Functional heartburn (A2)	Normal	Negative	None

The key distinguishing feature of reflux hypersensitivity is the combination of normal acid exposure with a positive symptom-reflux correlation. Functional heartburn (A2) shares normal acid exposure but has no symptom-reflux correlation and does not respond to antisecretory therapy.

Symptom-reflux association metrics

Symptom Index (SI)

Percentage of symptom episodes preceded by a reflux event within a 2-minute window. A value ≥50% is considered positive. Simple to calculate but does not account for total number of reflux events.

Symptom Association Probability (SAP)

A statistical measure (Fisher exact test) that evaluates whether the temporal association between reflux and symptoms exceeds what would be expected by chance. A value ≥95% is considered positive. SAP is generally preferred as it accounts for the total number of reflux events.

Acid Exposure Time (AET)

The percentage of time that the esophageal pH is <4. An AET <4% is considered normal (per the Lyon Consensus). An AET of 4-6% is inconclusive. In reflux hypersensitivity, the AET must be normal despite positive symptom association.

Required diagnostic workup

Upper endoscopy (EGD) with biopsies

Excludes erosive esophagitis, Barrett esophagus, and eosinophilic esophagitis (requires esophageal biopsies with ≥15 eosinophils per high-power field). Should be performed off PPI for 2-4 weeks when evaluating for EoE.

Ambulatory reflux monitoring (pH or pH-impedance)

The central test for diagnosing reflux hypersensitivity. Must demonstrate normal acid exposure time (AET <4%) with positive symptom association (SI ≥50% or SAP ≥95%). pH-impedance is preferred as it detects both acid and non-acid reflux events. Can be performed on or off PPI therapy.

High-resolution manometry (HRM)

Excludes major esophageal motor disorders per the Chicago Classification (v4.0): achalasia (types I-III), EGJ outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, and absent contractility. Minor motor disorders (ineffective esophageal motility, fragmented peristalsis) do not exclude reflux hypersensitivity.

Management approach

Neuromodulators: Esophageal neuromodulators are the primary treatment. Low-dose tricyclic antidepressants (e.g., amitriptyline 10-25 mg at bedtime, titrated to 50 mg) are first-line. SSRIs (e.g., citalopram, sertraline) and SNRIs (e.g., venlafaxine) are alternatives.
Antisecretory therapy: Unlike functional heartburn, some patients with reflux hypersensitivity may respond to PPI therapy. Response to antisecretory therapy does not exclude the diagnosis. A trial may be continued if beneficial.
Psychological therapies: Cognitive behavioral therapy (CBT), esophageal-directed hypnotherapy, and mindfulness-based stress reduction have shown benefit in functional esophageal disorders.
Anti-reflux surgery: Unlike functional heartburn where surgery is contraindicated, selected patients with reflux hypersensitivity may benefit from surgical anti-reflux management given the demonstrated reflux-symptom association. Careful patient selection is essential.
Reassurance and education: Explain the condition and its benign nature. The esophagus is sensitive to physiologic reflux events that would not cause symptoms in most people.

Key references

Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal Disorders. Gastroenterology. 2016;150(6):1368-1379.
Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503.
Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351-1362.
Drossman DA, Hasler WL. Rome IV: Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-1261.
Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol.2012;107(11):1662-1667.

Practice caveats

Reflux hypersensitivity is a diagnosis of exclusion. Do not apply these criteria without completing the recommended workup (endoscopy with biopsies, ambulatory reflux monitoring, high-resolution manometry).
The distinction between reflux hypersensitivity (A3) and functional heartburn (A2) hinges on reflux-symptom correlation on ambulatory monitoring. Patients with no symptom association despite normal acid exposure have functional heartburn, not reflux hypersensitivity.
Reflux hypersensitivity may overlap with GERD. Rome IV allows for the possibility of coexisting pathologic reflux and visceral hypersensitivity.
Consider whether pH-impedance monitoring was performed on or off PPI, as this affects interpretation. Testing off PPI provides the most complete acid exposure data. Testing on PPI can still identify non-acid reflux-symptom associations.
In clinical practice, there is significant overlap among functional esophageal disorders. A multidisciplinary approach involving gastroenterology, behavioral medicine, and primary care optimizes outcomes.

Introduction

Reflux hypersensitivity, classified as Rome IV category A3, is a functional esophageal disorder characterized by typical reflux symptoms (heartburn and/or chest pain) triggered by physiologic reflux events in the setting of normal esophageal acid exposure. This condition was previously referred to as the "hypersensitive esophagus" and was reclassified under the updated Rome IV framework published in 2016 by the Rome Foundation. It occupies a distinct position within the functional esophageal disorders spectrum, falling between gastroesophageal reflux disease (GERD) and functional heartburn (Rome IV A2), and its recognition has been critical in improving the diagnostic precision for patients with refractory reflux-type symptoms.

The hallmark of reflux hypersensitivity is a positive symptom-reflux association on ambulatory reflux monitoring despite the absence of pathologic acid exposure. This distinguishes it from both erosive GERD and non-erosive reflux disease (NERD), where abnormal acid exposure is typically present, and from functional heartburn, where no temporal correlation between symptoms and reflux events can be demonstrated. Understanding this diagnostic entity is essential for clinicians evaluating patients whose reflux symptoms persist despite proton pump inhibitor (PPI) therapy and who have unremarkable endoscopic findings.

Historical Context and Evolution of the Diagnosis

The concept of esophageal hypersensitivity to reflux has evolved considerably over the past three decades. Early observations noted a subset of patients with typical heartburn who had normal 24-hour pH monitoring results yet demonstrated a clear temporal association between their symptoms and acid reflux episodes. These patients were initially labeled as having a "hypersensitive esophagus," a term that reflected the underlying enhanced visceral perception without implying structural or mucosal pathology.

Under the Rome III classification (2006), the hypersensitive esophagus was considered part of the functional heartburn category, which grouped together all patients with heartburn in the absence of GERD. This approach was limited because it conflated two mechanistically distinct populations: those whose symptoms correlated with reflux events (hypersensitive esophagus) and those whose symptoms bore no relationship to reflux at all (true functional heartburn).

Rome IV (2016) resolved this ambiguity by creating a separate diagnostic category, Reflux Hypersensitivity (A3), positioned between GERD and Functional Heartburn (A2). This reclassification was driven by several key insights:

Pathophysiologic distinction: Patients with reflux hypersensitivity have a clear reflux trigger for their symptoms, unlike those with functional heartburn, where central sensitization or esophageal hypervigilance dominates without a reflux correlate.
Therapeutic implications: Reflux hypersensitivity patients may respond to reflux-reducing strategies (including anti-reflux surgery in carefully selected cases), whereas functional heartburn patients are generally managed with neuromodulators and behavioral therapies.
Prognostic relevance: Recognizing reflux hypersensitivity as a distinct entity allows more accurate prognostication and avoids unnecessary escalation of acid-suppressive therapy in patients who are unlikely to benefit.

Pathophysiology

The pathophysiology of reflux hypersensitivity involves a complex interplay between peripheral esophageal sensitization, central nervous system processing, and psychological factors. Unlike GERD, where mucosal injury is driven by excessive acid exposure, reflux hypersensitivity arises from an amplified sensory response to physiologic levels of reflux.

Peripheral Sensitization

At the esophageal level, several mechanisms contribute to enhanced chemosensitivity and mechanosensitivity:

Dilated intercellular spaces (DIS): Even in the absence of visible mucosal erosions, transmission electron microscopy has demonstrated widened intercellular spaces in the esophageal epithelium of patients with reflux hypersensitivity. These spaces may permit greater penetration of acid and other refluxate components to subepithelial nociceptors.
Upregulation of acid-sensing ion channels (ASICs) and TRPV1 receptors: Transient receptor potential vanilloid 1 (TRPV1) receptors and acid-sensing ion channels on esophageal afferent neurons are sensitized, lowering the threshold for pain perception in response to brief, non-pathologic acid exposure.
Mucosal microinflammation: Subtle inflammatory infiltrates (mast cells, T lymphocytes, and eosinophils at subclinical levels) have been identified in esophageal biopsies, potentially contributing to nociceptor sensitization even when conventional histology appears normal.
Impaired mucosal barrier function: Baseline mucosal impedance measurements using intraluminal impedance catheters have shown reduced values in reflux hypersensitivity patients, suggesting compromised mucosal integrity that facilitates sensory nerve activation.

Central Sensitization and Visceral Hyperalgesia

Central mechanisms play an equally important role in symptom generation:

Dorsal horn hyperexcitability: Repeated stimulation of esophageal afferents leads to wind-up phenomena in spinal cord dorsal horn neurons, resulting in amplified signal transmission to higher brain centers.
Altered brain processing: Functional MRI and PET studies have demonstrated enhanced activation of pain-processing regions (insular cortex, anterior cingulate cortex, prefrontal cortex) in response to esophageal stimulation in patients with reflux hypersensitivity compared with healthy controls.
Descending facilitation: Impairment of descending pain-inhibitory pathways from the brainstem may reduce the natural modulatory capacity that normally dampens visceral nociception.

Psychological and Autonomic Factors

Anxiety, depression, somatization, and hypervigilance are frequently comorbid with reflux hypersensitivity and can amplify symptom perception. Autonomic nervous system dysfunction, including vagal hypotonicity and sympathetic overactivity, may further modulate esophageal sensitivity and motility. The brain-gut axis is increasingly recognized as central to the perpetuation of symptoms in this condition.

Rome IV Diagnostic Criteria

The Rome IV diagnostic criteria for reflux hypersensitivity require the presence of all of the following four diagnostic criteria, in addition to fulfillment of temporal requirements:

Diagnostic Criteria (All Must Be Met)

Retrosternal symptoms including heartburn and chest pain: The patient must report typical reflux-type symptoms localized behind the sternum. Heartburn (a rising burning sensation) and/or non-cardiac chest pain are the cardinal features. These symptoms should be clinically consistent with reflux-mediated esophageal stimulation rather than cardiac, pulmonary, or musculoskeletal etiologies.
Normal endoscopy and absence of evidence that eosinophilic esophagitis is the cause of symptoms: Upper gastrointestinal endoscopy must demonstrate no erosive esophagitis (i.e., no Los Angeles Grade A-D esophagitis), no Barrett's esophagus, and no other structural mucosal abnormality. Additionally, esophageal biopsies must exclude eosinophilic esophagitis (EoE) as the etiology, typically requiring fewer than 15 eosinophils per high-power field on biopsies from the distal and proximal esophagus.
Absence of major esophageal motor disorders: High-resolution manometry (HRM) must be performed to exclude the major disorders of peristalsis as defined by the Chicago Classification. Specifically, the following must be excluded: achalasia (types I, II, and III), esophagogastric junction (EGJ) outflow obstruction, diffuse esophageal spasm, jackhammer esophagus (hypercontractile esophagus), and absent contractility. Minor peristaltic abnormalities (ineffective esophageal motility, fragmented peristalsis) do not exclude the diagnosis.
Evidence of triggering of symptoms by reflux events despite normal acid exposure on pH or pH-impedance monitoring: Ambulatory reflux monitoring (either wireless pH capsule or catheter-based pH-impedance) must demonstrate normal esophageal acid exposure time (AET), defined as distal esophageal pH < 4 for less than 4% of the total monitoring period (or less than 6% according to the Lyon Consensus). Despite this normal acid exposure, there must be a positive symptom-reflux association, established by either the Symptom Index (SI ≥ 50%) or the Symptom Association Probability (SAP ≥ 95%). This criterion is the defining feature that separates reflux hypersensitivity from functional heartburn.

Important Note: Response to antisecretory therapy (PPIs or H2 receptor antagonists) does not exclude the diagnosis of reflux hypersensitivity. Some patients with this condition may experience partial symptom improvement on acid suppression because reducing the acidity of refluxate can attenuate (though not eliminate) symptom triggering.

Temporal Criteria (All Must Be Met)

In addition to the four diagnostic criteria above, the following temporal requirements must be satisfied:

Symptoms present for the last 3 months: The criteria must have been fulfilled for at least the last 3 consecutive months at the time of evaluation.
Symptom onset at least 6 months before diagnosis: The initial onset of retrosternal symptoms must have occurred at least 6 months prior to the current diagnostic evaluation.
Symptoms occur at least twice per week: Retrosternal symptoms must occur on average at least 2 days per week to meet the frequency threshold.

Diagnostic Workup and Clinical Evaluation

Establishing a diagnosis of reflux hypersensitivity requires a systematic and stepwise approach. The following investigations are essential:

Step 1: Upper Endoscopy with Biopsies

Upper gastrointestinal endoscopy is the first-line investigation for any patient presenting with refractory heartburn or chest pain. The goals are to:

Exclude erosive esophagitis, Barrett's esophagus, peptic strictures, and esophageal malignancy.
Obtain esophageal biopsies (at least 2-4 from the distal esophagus and 2-4 from the proximal/mid esophagus) to rule out eosinophilic esophagitis. Biopsies should ideally be taken after at least 8 weeks of PPI therapy to exclude PPI-responsive esophageal eosinophilia.
Assess for other mucosal abnormalities such as esophageal inlet patch, glycogenic acanthosis, or candidal esophagitis.

Step 2: High-Resolution Manometry (HRM)

HRM is performed to evaluate esophageal motor function and exclude major esophageal motor disorders. The study characterizes:

Lower esophageal sphincter (LES) basal pressure and relaxation.
EGJ morphology and contractile integral.
Peristaltic pattern, vigor, and completeness using the Chicago Classification v4.0 metrics (distal contractile integral, distal latency, intrabolus pressure).

HRM is particularly important for distinguishing reflux hypersensitivity from conditions like achalasia, which can present with heartburn-like symptoms due to fermentation of retained food in a non-emptying esophagus.

Step 3: Ambulatory Reflux Monitoring

This is the pivotal diagnostic test for reflux hypersensitivity. It can be performed using:

Wireless pH capsule (Bravo): A catheter-free system that provides up to 96 hours of pH recording. It measures only acid reflux but offers the advantage of longer monitoring and improved patient comfort. Particularly useful for detecting day-to-day variability in reflux patterns.
Catheter-based pH-impedance monitoring: The gold standard for comprehensive reflux assessment. It detects both acid and non-acid (weakly acidic and weakly alkaline) reflux events and provides data on bolus exposure, proximal extent, and chemical composition of refluxate. This is especially valuable in reflux hypersensitivity because some patients may be symptomatic from weakly acidic reflux events.

Key parameters to evaluate include:

Parameter	Normal Threshold	Significance
Acid Exposure Time (AET)	< 4% (conclusively normal)	Must be normal for reflux hypersensitivity diagnosis
Total reflux episodes	< 80 per 24 hours (impedance)	Elevated numbers support pathologic reflux burden
Symptom Index (SI)	≥ 50% considered positive	Proportion of symptom events preceded by reflux
Symptom Association Probability (SAP)	≥ 95% considered positive	Statistical probability of symptom-reflux association
Mean Nocturnal Baseline Impedance (MNBI)	> 2292 ohms (distal)	Low values suggest impaired mucosal integrity
Post-Reflux Swallow-Induced Peristaltic Wave (PSPW) Index	> 61%	Low index indicates impaired chemical clearance

For a diagnosis of reflux hypersensitivity, the AET must be normal while the SI and/or SAP must be positive. Adjunctive impedance metrics such as MNBI and PSPW index can provide additional supportive evidence of reflux-mediated esophageal sensitization.

Step 4: Additional Considerations

In selected cases, the following may be helpful:

Prolonged wireless pH monitoring (48-96 hours): Increases the diagnostic yield by capturing day-to-day variability in reflux patterns and symptom-reflux associations.
Reflux monitoring off PPI therapy: The Lyon Consensus recommends performing ambulatory reflux monitoring off PPI therapy (after a 7-day washout) when the pre-test probability of GERD is low, to establish the baseline reflux profile. Testing on PPI therapy may be appropriate when evaluating refractory symptoms in a patient with previously documented GERD.
Functional lumen imaging probe (FLIP): Though not required for diagnosis, FLIP can provide complementary information about EGJ compliance and distensibility, which may help guide treatment decisions (particularly regarding the suitability of anti-reflux procedures).

Differential Diagnosis

The differential diagnosis of reflux hypersensitivity is broad and requires careful consideration of overlapping conditions:

Functional Heartburn (Rome IV A2)

Functional heartburn is the closest diagnostic neighbor to reflux hypersensitivity. Both conditions present with typical reflux symptoms and normal endoscopy. The key distinguishing feature is the absence of any symptom-reflux association on ambulatory monitoring in functional heartburn. Patients with functional heartburn have both normal acid exposure and negative symptom association metrics (SI and SAP), indicating that their symptoms are generated independently of reflux events. This distinction is critical because management approaches differ: reflux-reduction strategies have limited utility in functional heartburn, whereas they may benefit selected patients with reflux hypersensitivity.

Non-Erosive Reflux Disease (NERD)

NERD is defined by typical reflux symptoms with normal endoscopy but abnormal acid exposure on ambulatory pH monitoring. The AET exceeds the pathologic threshold (> 6% by Lyon Consensus). NERD patients typically respond well to PPI therapy. The distinction from reflux hypersensitivity hinges on the acid exposure measurement: abnormal in NERD, normal in reflux hypersensitivity.

Erosive Esophagitis and GERD Complications

Erosive esophagitis (Los Angeles Grade A-D), Barrett's esophagus, and peptic strictures represent the mucosal injury spectrum of GERD. These diagnoses are excluded by a normal upper endoscopy, which is a prerequisite for reflux hypersensitivity.

Eosinophilic Esophagitis (EoE)

EoE can present with heartburn, chest pain, and dysphagia. Endoscopic findings may be subtle (rings, furrows, white plaques) or absent. Esophageal biopsies showing 15 or more eosinophils per high-power field establish the diagnosis. Exclusion of EoE through appropriate biopsies is a mandatory component of the reflux hypersensitivity diagnostic criteria.

Major Esophageal Motor Disorders

Achalasia (particularly type I and type III), EGJ outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, and absent contractility can all produce retrosternal symptoms mimicking heartburn. HRM is essential for excluding these conditions before a diagnosis of reflux hypersensitivity can be made.

Other Considerations

Cardiac chest pain: Always exclude cardiac etiologies (acute coronary syndrome, stable angina, pericarditis) before attributing chest pain to an esophageal cause, particularly in patients with cardiovascular risk factors.
Esophageal infections: Candidal, herpetic, and cytomegalovirus esophagitis should be considered in immunocompromised patients.
Medication-induced esophagitis: Pills such as bisphosphonates, NSAIDs, doxycycline, potassium chloride, and iron supplements can cause direct mucosal injury and reflux-like symptoms.
Rumination syndrome: Effortless regurgitation of recently ingested food may be confused with reflux. Impedance-manometry can differentiate rumination from true reflux.
Supragastric belching: May coexist with or mimic reflux symptoms and can be identified on impedance monitoring.

Management and Treatment

Managing reflux hypersensitivity requires a multimodal approach that addresses both the peripheral reflux trigger and the central amplification of symptoms. The therapeutic strategy should be individualized and often involves a combination of the following:

Lifestyle and Dietary Modifications

Although evidence for lifestyle modifications specifically in reflux hypersensitivity is limited, general reflux-reduction measures may provide symptomatic benefit:

Weight loss in overweight or obese patients (reduces transient lower esophageal sphincter relaxations and intra-abdominal pressure).
Elevation of the head of the bed by 6-8 inches for nocturnal symptoms.
Avoidance of late-night meals (at least 3 hours before recumbency).
Reduction of known trigger foods (fatty foods, chocolate, caffeine, alcohol, acidic foods, spicy foods), though this should be individualized and not overly restrictive.
Smoking cessation.
Avoiding tight-fitting garments that increase intra-abdominal pressure.

Acid-Suppressive Therapy

PPIs remain a reasonable first-line pharmacologic approach, as reducing the acidity of refluxate may attenuate symptom triggering even though total acid exposure is within normal limits. However, it is important to recognize that many patients with reflux hypersensitivity will have already failed or had incomplete response to PPI therapy, which is often what prompts the diagnostic workup. Optimization of PPI therapy (ensuring appropriate dosing, timing 30-60 minutes before meals, and adequate duration of trial) should be confirmed before labeling a patient as PPI-refractory. Add-on therapy with alginate-based preparations (which form a mechanical raft at the EGJ) may provide additional benefit, particularly for postprandial symptoms and weakly acidic reflux events.

Neuromodulators

Neuromodulator therapy is the cornerstone of treatment for reflux hypersensitivity, targeting the visceral hypersensitivity and central sensitization that drive symptom perception:

Tricyclic antidepressants (TCAs): Low-dose TCAs (amitriptyline, nortriptyline, imipramine) at 10-50 mg nightly are often first-line neuromodulators. They modulate pain perception through serotonergic and noradrenergic pathways and have demonstrated efficacy in functional esophageal disorders. Common side effects include dry mouth, constipation, drowsiness, and urinary retention.
Selective serotonin reuptake inhibitors (SSRIs): Agents such as fluoxetine, sertraline, and citalopram may be beneficial, particularly when anxiety or depression is comorbid. They have modest visceral analgesic properties and can reduce esophageal hypersensitivity.
Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine and duloxetine offer dual neurotransmitter modulation and may be particularly useful when both pain modulation and mood improvement are therapeutic goals.
Other agents: Trazodone (at low doses) has shown benefit in some studies of functional esophageal disorders. Pregabalin and gabapentin, while less studied in this specific population, may be considered for their visceral analgesic properties, particularly when other neuromodulators are ineffective or not tolerated.

Psychological Therapies

Given the prominent role of central processing and psychological comorbidity in reflux hypersensitivity, brain-gut behavioral therapies are increasingly recognized as important therapeutic interventions:

Cognitive behavioral therapy (CBT): Helps patients identify and modify maladaptive thought patterns and behaviors related to symptom perception and catastrophizing. CBT has demonstrated efficacy in functional gastrointestinal disorders and is applicable to reflux hypersensitivity.
Gut-directed hypnotherapy: Esophageal-directed hypnotherapy uses guided relaxation, mental imagery, and suggestion to modulate visceral sensitivity. Studies have shown sustained improvement in functional heartburn and reflux hypersensitivity symptoms, often persisting well beyond the treatment period.
Mindfulness-based stress reduction (MBSR): May reduce symptom severity by attenuating the hypervigilance and stress-response amplification that perpetuate the visceral pain cycle.
Relaxation techniques and diaphragmatic breathing: Diaphragmatic breathing exercises can strengthen the crural diaphragm contribution to the anti-reflux barrier and reduce transient LES relaxations, while simultaneously activating the parasympathetic nervous system to reduce visceral sensitivity.

Anti-Reflux Surgery and Endoscopic Therapies

In carefully selected patients with reflux hypersensitivity who have failed medical and behavioral therapies, anti-reflux intervention may be considered. The key principle is that the positive symptom-reflux association, which is a defining feature of the condition, suggests that reducing reflux events could translate to symptom improvement. However, outcomes of fundoplication in reflux hypersensitivity are less predictable than in patients with pathologic GERD, and patient selection is critical.

Laparoscopic fundoplication: May be considered when there is objective evidence of a mechanically defective anti-reflux barrier (e.g., large hiatal hernia, low LES pressure) in addition to the positive symptom-reflux association. Patients should be counseled that outcomes are less reliable than for classic GERD.
Magnetic sphincter augmentation (LINX device): Offers a less invasive alternative to fundoplication with potential reversibility. Limited data exist specifically for reflux hypersensitivity.
Transoral incisionless fundoplication (TIF): An endoscopic option for patients who are not candidates for or decline surgical fundoplication. Evidence for its efficacy in reflux hypersensitivity specifically is emerging.

Clinical Pearl: Before proceeding with anti-reflux intervention in reflux hypersensitivity, ensure that (1) the positive symptom-reflux association has been reproducibly demonstrated, (2) the patient has undergone an adequate trial of neuromodulators and behavioral therapy, and (3) a multidisciplinary discussion involving gastroenterology, esophageal surgery, and psychology has taken place. Patient expectations should be carefully managed.

Special Populations and Clinical Considerations

Reflux Hypersensitivity on PPI Therapy

Some patients with reflux hypersensitivity are identified during reflux monitoring performed while on PPI therapy (i.e., they have normal AET on treatment but a positive symptom-reflux association with weakly acidic or non-acid reflux events). In these cases, pH-impedance monitoring is essential because standard pH monitoring alone would miss the weakly acidic reflux events responsible for symptom triggering. The Lyon Consensus recommends that when evaluating refractory symptoms on PPI therapy, impedance should be included in the monitoring protocol to characterize the full spectrum of reflux events.

Overlap with Other Functional Esophageal Disorders

Reflux hypersensitivity may coexist with other functional esophageal disorders, including functional dysphagia (Rome IV A4) and functional chest pain (Rome IV A1). Patients with visceral hypersensitivity often demonstrate heightened sensitivity across multiple esophageal modalities (acid, distension, temperature). A comprehensive motility evaluation and thorough symptom characterization are necessary to identify overlapping diagnoses and tailor treatment accordingly.

The Borderline AET Zone

The Lyon Consensus introduced the concept of an inconclusive or borderline AET zone (4-6%) where the diagnosis of pathologic reflux is uncertain. Patients falling within this zone who have a positive symptom-reflux association may represent a spectrum between true GERD and reflux hypersensitivity. Adjunctive metrics such as total reflux episodes, MNBI, and PSPW index become particularly important for diagnostic categorization in these borderline cases. Repeated or prolonged monitoring may also help resolve diagnostic uncertainty.

Post-Fundoplication Reflux Hypersensitivity

Patients who develop new or persistent reflux-type symptoms following anti-reflux surgery may meet criteria for reflux hypersensitivity. Esophageal sensitization from prior reflux exposure, altered esophageal mechanics post-surgery, and psychological factors related to unmet expectations can all contribute. These patients require careful re-evaluation with endoscopy, HRM, and ambulatory reflux monitoring before attributing symptoms to reflux hypersensitivity rather than wrap failure, recurrent hernia, or other surgical complications.

Practical Algorithm for Clinicians

The following stepwise approach summarizes the diagnostic pathway for suspected reflux hypersensitivity:

Clinical assessment: Confirm retrosternal symptoms (heartburn and/or chest pain) occurring at least twice weekly for 3 months, with onset at least 6 months ago. Exclude cardiac causes if chest pain is prominent.
Upper endoscopy with biopsies: Confirm normal mucosa. Obtain esophageal biopsies to exclude EoE (proximal and distal esophagus, at least 6 biopsies total).
High-resolution manometry: Exclude achalasia, EGJ outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, and absent contractility.
Ambulatory reflux monitoring: Perform pH-impedance monitoring (preferred over pH-only) off PPI therapy (if assessing baseline reflux profile) or on PPI therapy (if evaluating refractory symptoms in known GERD). Document normal AET and positive SI and/or SAP.
Diagnosis confirmed: If all diagnostic and temporal criteria are met, the diagnosis of reflux hypersensitivity (Rome IV A3) is established.
Initiate multimodal therapy: Combine lifestyle modifications, optimized acid suppression, neuromodulators, and psychological therapies as indicated.

Prognosis and Long-Term Outcomes

Reflux hypersensitivity is a chronic condition that often requires sustained, multimodal management. Natural history studies suggest that some patients may transition between diagnostic categories over time: a proportion of reflux hypersensitivity patients may evolve into functional heartburn (with loss of the positive symptom-reflux association) or, less commonly, develop pathologic acid exposure consistent with NERD or GERD. Periodic reassessment may be appropriate in patients with changing symptom patterns or refractory symptoms.

With appropriate therapy, particularly the combination of neuromodulators and brain-gut behavioral therapies, many patients achieve meaningful symptom improvement. Setting realistic expectations is important: the goal of treatment is to reduce symptom frequency and severity to a level that minimizes functional impairment, rather than achieving complete symptom elimination. Patient education about the nature of visceral hypersensitivity, reassurance regarding the absence of structural disease, and a strong therapeutic alliance are foundational to successful management.